---
title: European intersocietal recommendations for the biomarker-based diagnosis of
  neurocognitive disorders
date: '2024-02-16'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38365381/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240217170652&v=2.18.0
source: heidelberg[Affiliation]
description: The recent commercialisation of the first disease-modifying drugs for
  Alzheimer's disease emphasises the need for consensus recommendations on the rational
  use of biomarkers to diagnose people with suspected neurocognitive disorders in
  memory clinics. Most available recommendations and guidelines are either disease-centred
  or biomarker-centred. A European multidisciplinary taskforce consisting of 22 experts
  from 11 European scientific societies set out to define the first ...
disable_comments: true
---
The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease emphasises the need for consensus recommendations on the rational use of biomarkers to diagnose people with suspected neurocognitive disorders in memory clinics. Most available recommendations and guidelines are either disease-centred or biomarker-centred. A European multidisciplinary taskforce consisting of 22 experts from 11 European scientific societies set out to define the first ...